Filing step-change
VIVOBIOT · 2026-08
Quarterly observations that moved versus the prior period in 2026-08. Facts only — not a call to act.
Narrative date 2026-08-30 · Evidence medium
Vivo Biotech witnessed a significant acceleration in its 75.73% gross margin, up from 10.65%, in the latest quarterly update.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 75.73 % | 10.65 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 10.65 % | 11.12 | ▼ |
| REVENUE_GROWTH_YOY | 14.1 % | -89.2 | ▲ |
Cite this
Source: Samhati filing step-change for VIVOBIOT (2026-08). Observation: Vivo Biotech witnessed a significant acceleration in its 75.73% gross margin, up from 10.65%, in the latest quarterly update. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/vivobiot/q/2026-08
Other periods